Xbrane Biopharma AB 2024 Integrated Report
Company: Xbrane Biopharma AB
Sector: Manufacturing
Country: Sweden
Year: 2024
Type: Integrated Report
Pages: 80
The report describes Xbrane's 2024 performance as it expanded Ximluci® to 21 markets and generated group revenue of SEK 198.7 million. It highlights treatment access for an estimated 7,000 patients and EUR 6 million in estimated societal savings. Environmental reporting records no Scope 1 emissions and 8 ton CO2e of Scope 2 emissions, while the company continued improving Scope 3 measurement. The sustainability section also reports 65 year-end employees, 60% women on the Board, Great Place to Work® certification and participation in the UN Global Compact.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.